Get the Weekly Intelligence Brief — top committee picks every Sunday.

HSIC vs SGRY

Henry Schein vs Surgery Partners, Inc. — AI-powered side-by-side comparison
HSIC
Henry Schein
67
Buy
VS
SGRY
Surgery Partners, Inc.
48
Watch
MetricHSICSGRY
AI Score 67 48
Price $89.16 $15.02
P/E Ratio 25.77× -21.74×
ROE 12.3% -4.5%
Revenue Growth YoY
Gross Margin 30.3% 21.4%
Debt / Equity 1.21× 2.40×
Dividend Yield 0.0% 0.0%
RSI (14) 59.4 42.3
Beta 0.808 1.937
Expected Upside +0.8%

AI Committee View

Current Innellis committee reasoning for HSIC versus SGRY.
HSIC leads by 19 points.

HSIC scores 67/100 (Buy) versus SGRY at 48/100 (Watch).

HSIC Committee View
75% agreement
4 analysts

The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is growth rate is decelerating quarter over quarter -- the trend line matters more than the level. The committee is constructive but not yet at full conviction.

Bull Case
  • 4 consecutive earnings beats -- consistent execution — Growth
  • Price structure making higher highs and higher lows — Technical
  • MACD histogram positive -- bullish momentum — Technical
Bear Case
  • Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
SGRY Committee View
33% agreement
6 analysts

The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Growth Analyst remains cautious — revenue declining -20.5% yoy -- this is not a growth story right now. This disagreement is itself the signal — the setup is not clean in either direction.

Bull Case
  • Price-to-book of 1.2x is a discount to asset value — Value
  • VIX regime is low -- calm backdrop supports risk-taking — Macro
  • Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
  • ROE of only -4.6% -- cheap may mean cheap for a reason — Value
  • Debt-to-equity of 2.16 adds balance-sheet risk to the value case — Value
  • Revenue declining -20.5% YoY -- this is not a growth story right now — Growth
Want the full breakdown?
Committee votes, technicals, and trade plans for both companies.
HSIC Full Analysis SGRY Full Analysis